The Digital Pathology Revolution: Breaking the Glass Ceiling
This article was originally published in Start Up
Executive Summary
Among diagnostic specialties, anatomic pathology is the last holdout against the digital revolution. Pathologists still detect disease by looking at tissue samples on a glass slide through a microscope, just as they have done for a hundred years. But in the last couple of years, start-up companies have begun to break the bondage of pathologists to slides. Their solution: platforms for digitizing slides so they can be accessed through computer networks by clinicians anywhere in the world. Two start-ups, Aperio and BioImagene, have led the way and now all the big imaging manufacturers, the microscope companies and biomarker developers want in.
You may also be interested in...
Medtech Risk Capital? Anything But. A VC Roundtable from IN3
A year and a half after the September 2008 collapse of Lehman Brothers and the official start of the economic recession, a panel of venture capitalists and other financiers in the medical device industry came together at the IN3 meeting in Boston. We asked them if they've had to change the way they look at deals. What is the trade-off between expensive, de-risked later stage deals and the kinds of returns that can be achieved by backing a winning company from start to finish? Where would they place their bets: cost-effective technologies for tried-and-true markets or novel products for unmet clinical needs, the "evolutionary vs. revolutionary" debate? And what can one do about tired syndicates? Our panel lets us in on the kinds of discussions they've been having around the table at weekly partners' meetings.
Medtech Risk Capital? Anything But. A VC Roundtable from IN3
A year and a half after the September 2008 collapse of Lehman Brothers and the official start of the economic recession, a panel of venture capitalists and other financiers in the medical device industry came together at the IN3 meeting in Boston. We asked them if they've had to change the way they look at deals. What is the trade-off between expensive, de-risked later stage deals and the kinds of returns that can be achieved by backing a winning company from start to finish? Where would they place their bets: cost-effective technologies for tried-and-true markets or novel products for unmet clinical needs, the "evolutionary vs. revolutionary" debate? And what can one do about tired syndicates? Our panel lets us in on the kinds of discussions they've been having around the table at weekly partners' meetings.
Mauna Kea Technologies SAS
Mauna Kea Technologies is developing Cellvizio, a tiny confocal laser microscopy system small enough to be inserted into the colon, the urinary tract, the lungs, deep in the brain, and other small spaces in the body. Today, every procedure in gastroenterology--a biopsy or a therapeutic intervention-- is already the second, third, or later step in a process that becomes cumbersome simply because clinicians can't get the relevant information from the first step, which is endoscopy. That's where Cellvizio brings advantages, providing a real-time, in vivo microscopic image of tissue to properly characterize it, so a gastroenterologist can both determine and efficiently carry out the proper course of treatment for a particular patient. Cellvizio's most compelling initial applications include the diagnosis of biliary strictures, Barrett's Esophagus, and colonoscopy.